{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:52:26Z","timestamp":1791489146124,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T00:00:00Z","timestamp":1572652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T00:00:00Z","timestamp":1572652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40262-019-00823-8","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T04:41:34Z","timestamp":1572669694000},"page":"463-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies"],"prefix":"10.1007","volume":"59","author":[{"given":"John David","family":"Clements","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mita","family":"Kuchimanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Terminello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3843-8097","authenticated-orcid":false,"given":"Sameer","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,2]]},"reference":[{"key":"823_CR1","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/cncr.29383","volume":"121","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, O\u2019Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015;121:2517\u201328.","journal-title":"Cancer"},{"key":"823_CR2","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/ped.12837","volume":"57","author":"H Goto","year":"2015","unstructured":"Goto H. Childhood relapsed acute lymphoblastic leukemia: biology and recent treatment progress. Pediatr Int. 2015;57:1059\u201366.","journal-title":"Pediatr Int"},{"key":"823_CR3","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Anderson","year":"1984","unstructured":"Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63:1424\u201333.","journal-title":"Blood"},{"key":"823_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/jcp.51.5.364","volume":"51","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51:364\u20139.","journal-title":"J Clin Pathol"},{"key":"823_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/asheducation-2001.1.194","volume":"2001","author":"NL Harris","year":"2001","unstructured":"Harris NL, Stein H, Coupland SE, Hummel M, Favera RD, Pasqualucci L, et al. New approaches to lymphoma diagnosis. Hematol Am Soc Hematol Educ Progr. 2001;2001:194\u2013220.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"823_CR6","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","volume":"68","author":"HM Horton","year":"2008","unstructured":"Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68:8049\u201357.","journal-title":"Cancer Res"},{"key":"823_CR7","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","volume":"95","author":"A Loffler","year":"2000","unstructured":"Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 \u00d7 CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95:2098\u2013103.","journal-title":"Blood"},{"key":"823_CR8","unstructured":"Amgen Inc. Blinatumomab USPI. \nhttp:\/\/pi.amgen.com\/united_states\/blincyto\/blincyto_pi_hcp_english.pdf\n\n. Accessed 6 Dec 2018."},{"key":"823_CR9","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21:4035\u20139.","journal-title":"Clin Cancer Res"},{"key":"823_CR10","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","volume":"126","author":"G Zugmaier","year":"2015","unstructured":"Zugmaier G, Gokbuget N, Klinger M, Viardot A, Stelljes M, Neumann S, et al. Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126:2578\u201384.","journal-title":"Blood"},{"key":"823_CR11","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","volume":"34","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34:1104\u201311.","journal-title":"J Clin Oncol"},{"key":"823_CR12","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331.","journal-title":"Blood"},{"key":"823_CR13","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226\u201333.","journal-title":"Blood"},{"key":"823_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, Gokbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57\u201366.","journal-title":"Lancet Oncol."},{"key":"823_CR15","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134\u201340.","journal-title":"J Clin Oncol"},{"key":"823_CR16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2016;127:1410\u20136.","journal-title":"Blood"},{"key":"823_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","volume":"55","author":"M Zhu","year":"2016","unstructured":"Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, et al. Blinatumomab, a bispecific T-cell engager (BiTE\u00ae) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin Pharmacokinet. 2016;55:1271\u201388.","journal-title":"Clin Pharmacokinet"},{"key":"823_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"key":"823_CR19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"N Engl J Med"},{"key":"823_CR20","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, Gokbuget N, Topp MS, et al. Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35:1795\u2013802.","journal-title":"J Clin Oncol"},{"key":"823_CR21","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381\u20139.","journal-title":"J Clin Oncol"},{"key":"823_CR22","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974\u20137.","journal-title":"Science"},{"key":"823_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3109\/03602538409015064","volume":"15","author":"SL Beal","year":"1984","unstructured":"Beal SL. Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab Rev. 1984;15:173\u201393.","journal-title":"Drug Metab Rev"},{"key":"823_CR24","volume-title":"NONMEM user\u2019s guides","author":"S Beal","year":"2009","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user\u2019s guides. Ellicott City: Icon Development Solutions; 2009."},{"key":"823_CR25","unstructured":"Bauer RJ. NONMEM users guide introduction to NONMEM 7.2.0. Ellicott City: Icon Development Solutions; 2011."},{"key":"823_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35:185\u2013202.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"823_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An introduction to the bootstrap","author":"B Efron","year":"1993","unstructured":"Efron B, Tibshirani R. An introduction to the bootstrap. London: Chapman and Hall; 1993."},{"key":"823_CR28","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1023\/A:1011958717142","volume":"15","author":"CA Hunt","year":"1998","unstructured":"Hunt CA, Givens GH, Guzy S. Bootstrapping for pharmacokinetic models: visualization of predictive and parameter uncertainty. Pharm Res. 1998;15:690\u20137.","journal-title":"Pharm Res"},{"key":"823_CR29","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645\u201368.","journal-title":"J Pharm Sci"},{"key":"823_CR30","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/cpt.651","volume":"101","author":"T Yuraszeck","year":"2017","unstructured":"Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment. Clin Pharmacol Ther. 2017;101:634\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"823_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1542\/pir.34-6-258","volume":"34","author":"J Wagner","year":"2013","unstructured":"Wagner J, Abdel-Rahman SM. Pediatric pharmacokinetics. Pediatr Rev. 2013;34:258\u201369.","journal-title":"Pediatr Rev"},{"key":"823_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/pharmaceutics2040389","volume":"2","author":"R Shi","year":"2010","unstructured":"Shi R, Derendorf H. Pediatric dosing and body size in biotherapeutics. Pharmaceutics. 2010;2:389\u2013418.","journal-title":"Pharmaceutics."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00823-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00823-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00823-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T20:39:34Z","timestamp":1604176774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00823-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,2]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00823-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,2]]},"assertion":[{"value":"2 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Amgen Inc. Amgen designed the study, and collected, analyzed, and interpreted the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"John D. Clements, Bianca Terminello, and Sameer Doshi are employees of and shareholders in Amgen Inc. Min Zhu and Mita Kuchimanchi were employees of and shareholders in Amgen Inc. when the analysis was conducted. Min Zhu is currently employed by Regeneron. Mita Kuchimanchi is currently employed by Biogen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments, or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}